financetom
Business
financetom
/
Business
/
Senior UK lawmaker flags concerns about Shein to LSE and regulator
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Senior UK lawmaker flags concerns about Shein to LSE and regulator
Jan 10, 2025 9:57 AM

LONDON (Reuters) -The chair of a British parliamentary committee wrote on Thursday to the London Stock Exchange ( LDNXF ) to raise concerns about evidence given by a Shein representative at a hearing this week, and to ask how the exchange checks statements by firms looking to list.

The lack of response by Shein's general counsel for Europe, the Middle East and Africa to lawmakers' questions about its supply chain at a committee hearing on Tuesday made lawmakers "profoundly concerned", chair Liam Byrne said in the letter to the LSE CEO Julia Hoggett.

Online fast-fashion retailer Shein is working towards a London IPO in the first half of this year but has faced scrutiny over its mainly China-based suppliers and working practices.

In the letter Byrne asked "what checks, if any, the London Stock Exchange ( LDNXF ) has in place to authenticate statements by firms seeking to list, with particular regard to their safeguards against the use of forced labour in their products."

Byrne also wrote to Britain's financial regulator, which is in charge of assessing and approving stock market listings such as Shein's, asking it how it ensures all legal risks are disclosed prior to an IPO.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Kazia Therapeutics (KZIA) Stock Surges 77% On Positive Preclinical Data For Breast Cancer Drug
Kazia Therapeutics (KZIA) Stock Surges 77% On Positive Preclinical Data For Breast Cancer Drug
Jun 11, 2025
Shares of Kazia Therapeutics Ltd ( KZIA ) are surging Wednesday following the announcement of preclinical research findings for its lead drug candidate, paxalisib. What To Know: The clinical-stage biotechnology revealed data published in the peer-reviewed journal Molecular Cancer Therapeutics highlighting paxalisib’s potential in treating triple-negative breast cancer. The research, conducted at the QIMR Berghofer Medical Research Institute, demonstrated that...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
US FDA approves Nuvation Bio's lung cancer therapy
US FDA approves Nuvation Bio's lung cancer therapy
Jun 11, 2025
June 11 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's ( NUVB ) therapy for patients with a type of lung cancer. (Reporting by Siddhi Mahatole in Bengaluru; Editing by Shinjini Ganguli) ...
--Nuvation Bio Stock Trading Halted, Pending Material News Release
--Nuvation Bio Stock Trading Halted, Pending Material News Release
Jun 11, 2025
01:06 PM EDT, 06/11/2025 (MT Newswires) -- Price: 2.37, Change: -0.16, Percent Change: -6.32 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved